Business Context and Reporting Period
The filing is Bond Laboratories, Inc.’s Form 10-K for the fiscal year ended December 31, 2012; the source text does not identify FitLife Brands, Inc. The company develops and markets nutritional supplements through its wholly owned NDS Nutrition Products subsidiary, principally through GNC franchisees. It marketed approximately 50 products to more than 800 GNC franchise locations and customers in eight additional countries.
GNC franchise sales represented approximately 97% of 2012 revenue, creating substantial customer concentration. The company introduced seven new products during 2012 and discontinued its Fusion Premium Beverages division at the end of 2011.
Financial Performance and Position
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Revenue | $18.09 million | $12.09 million | +$6.00 million, approximately 49.6% |
| Gross profit | $6.52 million | $4.15 million | Approximately 36.1% vs. 34.3% margin |
| Operating income | $1.88 million | $0.21 million | Approximately 10.4% vs. 1.7% margin |
| Net income | $2.52 million | $0.33 million | Increase of $2.20 million |
| Basic earnings per share | $0.03 | $0.00 | Improved |
| Cash flow from operations | $0.58 million | $0.10 million | Increase of $0.48 million |
- Cost of goods sold increased to $11.57 million from $7.94 million.
- General and administrative expense increased to $2.19 million from $2.06 million, while selling and marketing expense increased to $2.21 million from $1.62 million.
- 2012 net income included a $648,743 income tax benefit, including recognition of a $689,000 deferred tax asset. The company reported approximately $22.6 million of federal net operating loss carryforwards, subject to potential limitations.
- Cash increased to $936,911 from $354,929. Accounts receivable were $969,111, and inventory increased sharply to $3.68 million from $1.88 million.
- Total assets were $7.68 million and total liabilities were $1.87 million at December 31, 2012. Stockholders’ equity was $5.81 million.
- The company had $437,089 outstanding under a $2.0 million revolving credit facility. The facility bears interest at 3.0% plus one-month LIBOR, is secured by specified receivables and inventory, and was scheduled to mature on May 15, 2013.
- Cash flow from investing activities was zero, and cash flow from financing activities was zero in 2012. The company did not sell securities for cash during the year.
- Basic and diluted weighted-average shares were 74.5 million and 93.8 million, respectively. At December 31, 2012, 8.9 million warrants and 1.2 million options were outstanding, in addition to convertible preferred stock.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven by higher sales of existing products, greater average sales per retail location, new product introductions, additional GNC locations, and initial international expansion.
- Gross margin improved to approximately 36.1% from 34.3%, while operating margin increased substantially to approximately 10.4% from 1.7%.
- Net income increased more than sevenfold, although the 2012 result benefited materially from the income tax benefit.
- Operating cash flow improved despite a $1.81 million increase in inventory and a $689,000 increase in the deferred tax asset.
- The company paid $250,000 in connection with the Schick litigation settlement and expected to pay an additional $105,000 through December 31, 2013.
- GNC concentration remained significant: GNC franchisees accounted for $17.55 million, or approximately 97%, of 2012 sales.
- The company voluntarily reformulated products containing DMAA; as of June 2012, none of its products contained DMAA.
- Common shares outstanding increased to 74.75 million from 74.17 million, primarily reflecting shares issued for services and employee awards. No shares were issued to investors for cash.
Guidance, Outlook, Risks, Contingencies and Unusual Items
- Management expected cash from operations, existing cash, and other resources to fund liquidity through at least December 31, 2013, while acknowledging that continued positive operating cash flow is necessary.
- Management identified international expansion, additional GNC locations, increased average sales per location, and broader distribution of Core Active Nutrition products as potential growth drivers.
- Management anticipated that legal costs could decline in 2013 and that selling and marketing expense would continue to increase with sales, but potentially at a slower rate than revenue.
- Key risks include dependence on GNC franchisees, competition from larger companies, reliance on third-party manufacturers and suppliers, regulatory requirements affecting dietary supplements and advertising, product liability and recall exposure, and uncertainty regarding product efficacy and safety.
- The company relies on contract manufacturers and does not independently verify all product composition, increasing potential exposure to manufacturing errors, contamination, recalls, and claims.
- The CycloBolan product liability matter remained pending. The plaintiff sought damages believed to exceed $500,000; the insurer assumed the defense, and management considered the company’s overall risk minimal. The filing does not provide a clear estimated loss.
- The filing states that management concluded disclosure controls and internal control over financial reporting were effective. The external auditor did not provide an internal-control attestation because the company qualified for the smaller-reporting-company exemption.
- The company has never paid cash dividends and does not anticipate paying dividends in the foreseeable future.
Important Facts for Investors to Verify
- Confirm the issuer identity: the provided filing is for Bond Laboratories, Inc., not FitLife Brands, Inc.
- Reconcile the effect of the $648,743 tax benefit and the $689,000 deferred tax asset on reported profitability and cash generation.
- Review the maturity, renewal, and repayment status of the $437,089 revolving credit balance after its May 15, 2013 maturity date.
- Assess the sustainability of revenue given that approximately 97% came from GNC franchisees that were not required to purchase the company’s products.
- Evaluate inventory growth from $1.88 million to $3.68 million, including sell-through, obsolescence, and working-capital implications.
- Review dilution from 8.9 million warrants, 1.2 million options, and convertible preferred stock representing 5.0 million potential common shares.
- Monitor the CycloBolan litigation, the remaining $105,000 expected Schick settlement payments, and any additional product-liability or regulatory exposure.
- Consider that 2012 earnings benefited from a tax item and may not represent recurring after-tax profitability.